Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients
OBJECTIVES: The aim of this study was to evaluate the cost‑effectiveness of apixaban in the prevention of thromboembolic events in patients with non‑valvular atrial fibrillation (NVAF) relatively to standard of care (warfarin or aspirin) from the Italian National Health System (SSN) perspective. MET...
Main Authors: | Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2014-12-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/974 |
Similar Items
-
PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01) -
Apixaban
by: Gianluca Airoldi, et al.
Published: (2013-03-01) -
Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
by: Matthew A. Wanat, et al.
Published: (2019-10-01) -
COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2015-09-01) -
Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis
by: Benjamin J. R. Buckley, et al.
Published: (2022-06-01)